PE20170519A1 - Anticuerpos antagonistas del interferon alfa y omega - Google Patents

Anticuerpos antagonistas del interferon alfa y omega

Info

Publication number
PE20170519A1
PE20170519A1 PE2016002764A PE2016002764A PE20170519A1 PE 20170519 A1 PE20170519 A1 PE 20170519A1 PE 2016002764 A PE2016002764 A PE 2016002764A PE 2016002764 A PE2016002764 A PE 2016002764A PE 20170519 A1 PE20170519 A1 PE 20170519A1
Authority
PE
Peru
Prior art keywords
omega
interferon alpha
alpha
ifn
refers
Prior art date
Application number
PE2016002764A
Other languages
English (en)
Inventor
Ronald Swanson
Galina Obmolova
Christian Martinez
Lu Lu
Ellen Chi
Xiefan Lin-Schmidt
Jarrat Jordan
Chichi Huang
Judith Connor
Jinquan Luo
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20170519A1 publication Critical patent/PE20170519A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)

Abstract

Se refiere a un anticuerpo monoclonal aislado que se une a, y neutraliza una actividad biologica de un interferon omega humano (IFN-omega) y al menos tres, cuatro, cinco, seis, siete, ocho, nueve, diez u once subtipos de interferon alfa humanos (IFN-alfa). Tambien se refiere a una composicion farmaceutica. Dicho anticuerpo es util en el tratamiento de enfermedades inflamatorias o autoinmunes tales como el lupus, diabetes de tipo I, entre otras
PE2016002764A 2014-06-23 2015-06-22 Anticuerpos antagonistas del interferon alfa y omega PE20170519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462015765P 2014-06-23 2014-06-23

Publications (1)

Publication Number Publication Date
PE20170519A1 true PE20170519A1 (es) 2017-05-11

Family

ID=54869049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002764A PE20170519A1 (es) 2014-06-23 2015-06-22 Anticuerpos antagonistas del interferon alfa y omega

Country Status (26)

Country Link
US (3) US10208113B2 (es)
EP (1) EP3157564A4 (es)
JP (2) JP6756625B2 (es)
KR (2) KR102553752B1 (es)
CN (1) CN106573053B (es)
AR (1) AR100944A1 (es)
AU (1) AU2015280275B2 (es)
CA (1) CA2952965C (es)
CL (1) CL2016003291A1 (es)
CR (1) CR20160593A (es)
DO (1) DOP2016000334A (es)
EA (1) EA039946B1 (es)
EC (1) ECSP17003946A (es)
IL (1) IL249477B (es)
JO (1) JO3607B1 (es)
MX (1) MX2016017380A (es)
MY (1) MY182046A (es)
PE (1) PE20170519A1 (es)
PH (1) PH12016502535A1 (es)
SG (1) SG11201610497RA (es)
SV (1) SV2016005352A (es)
TW (1) TWI713453B (es)
UA (1) UA123001C2 (es)
UY (1) UY36187A (es)
WO (1) WO2015200165A1 (es)
ZA (1) ZA201700483B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801599A1 (en) * 2018-06-01 2021-04-14 ILC Therapeutics Ltd Compositions and methods relating to the treatment of diseases
EP3873523A4 (en) * 2018-10-26 2022-08-10 Janssen Biotech, Inc. TYPE I INTERFERON SIGNATURES AND METHODS OF USE
JP2022527542A (ja) * 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法
WO2021108109A1 (en) * 2019-11-26 2021-06-03 Beijing Xuanyi Pharmasciences Co., Ltd. Modulators of t-cell activity
MX2022006578A (es) * 2019-12-17 2022-07-04 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos.
CN111087461B (zh) * 2020-01-13 2022-06-14 武汉科前生物股份有限公司 一种重组蛋白、编码该重组蛋白的核酸及其应用
EP4355759A1 (en) 2021-06-18 2024-04-24 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
CN113584149A (zh) * 2021-07-09 2021-11-02 中国疾病预防控制中心性病艾滋病预防控制中心 用于检测hiv感染者免疫重建状况的试剂和方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0490233A1 (de) * 1986-03-10 1992-06-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990004026A1 (en) 1988-10-11 1990-04-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce New plasmid constructions for high level production of eukaryotic proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2368737T3 (es) * 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
DK1641483T3 (da) * 2003-06-12 2008-06-02 Lilly Co Eli Fusionsproteiner
LT2418220T (lt) * 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
PT2662390T (pt) * 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc ANTI-CD154 ANTIBODIES
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
MX2009001620A (es) 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CA2681530C (en) 2007-03-22 2017-03-28 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101687032B1 (ko) 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
JP5789192B2 (ja) 2008-11-13 2015-10-07 フェムタ ファーマシューティカルズ インコーポレイテッドＦｅｍｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒト化抗ｉｌ−６抗体
WO2010088444A1 (en) 2009-01-29 2010-08-05 Medimmune, Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012010280B1 (pt) 2009-10-30 2020-09-24 Janssen Biotech, Inc. Anticorpo isolado ou fragmento do mesmo que se liga especificamente a il-17a humana, seu uso, e composição farmacêutica
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
CN102812039B (zh) * 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
US20140027648A1 (en) 2011-09-22 2014-01-30 Sture Petersson Neutron Detector
SG10201710574UA (en) 2012-03-15 2018-02-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
AU2014235003A1 (en) * 2013-03-15 2015-09-17 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
WO2015001013A2 (en) * 2013-07-03 2015-01-08 Immunoqure Ag Human anti-ifn-alpha antibodies

Also Published As

Publication number Publication date
US20150368338A1 (en) 2015-12-24
AU2015280275A1 (en) 2017-01-05
IL249477A0 (en) 2017-02-28
BR112016030202A2 (pt) 2017-11-14
JP6893970B2 (ja) 2021-06-23
CL2016003291A1 (es) 2017-09-08
KR20230107409A (ko) 2023-07-14
MY182046A (en) 2021-01-18
US10358491B2 (en) 2019-07-23
US20190106489A1 (en) 2019-04-11
CA2952965C (en) 2024-01-23
EP3157564A4 (en) 2018-01-03
CN106573053B (zh) 2021-12-28
AR100944A1 (es) 2016-11-09
PH12016502535A1 (en) 2017-04-10
JP2017528118A (ja) 2017-09-28
UA123001C2 (uk) 2021-02-03
ZA201700483B (en) 2018-12-19
EA201790057A1 (ru) 2017-05-31
WO2015200165A1 (en) 2015-12-30
DOP2016000334A (es) 2017-09-15
JP6756625B2 (ja) 2020-09-16
KR20170020477A (ko) 2017-02-22
AU2015280275B2 (en) 2021-02-25
US10759854B2 (en) 2020-09-01
SG11201610497RA (en) 2017-01-27
EA039946B1 (ru) 2022-03-31
UY36187A (es) 2016-01-08
CN106573053A (zh) 2017-04-19
US20190359705A1 (en) 2019-11-28
TW201613967A (en) 2016-04-16
IL249477B (en) 2020-09-30
CA2952965A1 (en) 2015-12-30
EP3157564A1 (en) 2017-04-26
TWI713453B (zh) 2020-12-21
SV2016005352A (es) 2017-05-03
KR102553752B1 (ko) 2023-07-07
MX2016017380A (es) 2017-08-02
JO3607B1 (ar) 2020-08-27
CR20160593A (es) 2017-02-21
JP2020073499A (ja) 2020-05-14
US10208113B2 (en) 2019-02-19
ECSP17003946A (es) 2018-04-30

Similar Documents

Publication Publication Date Title
PE20170519A1 (es) Anticuerpos antagonistas del interferon alfa y omega
AR110414A1 (es) Anticuerpos que se unen específicamente a il-15 humana y usos de estos
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
SV2018005678A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CO7400885A2 (es) Análogos de glucagón
NI201300057A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
UY33202A (es) Proteínas de unión a cd127
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20130646A1 (es) Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EA201690803A1 (ru) Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
UY37456A (es) Inmunoglobulinas y sus usos
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CO2019008946A2 (es) Anticuerpos anti-tgf-beta y su uso
BR112017008416A2 (pt) ?produtos terapêuticos à base de lantionina sintetase c-like 2?.